Search
Ravagalimab
go.drugbank.com/drugs/DB16676InvestigationalRavagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis
Dithioerythritol
go.drugbank.com/drugs/DB01692ExperimentalA compound that, along with its isomer, Cleland's reagent (dithiothreitol), is used for the protection of sulfhydryl groups against oxidation to disulfides and for the reduction of disulfides to sulfhydryl
Categories: Compounds used in a research, industrial, or household settingILY101
go.drugbank.com/drugs/DB05059InvestigationalILY101 is designed to allow for lower daily doses and improved patient acceptance and tolerability in comparison to other products in this class of drugs. … ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate.
Propiomazine
go.drugbank.com/drugs/DB00777ApprovedPropiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. … Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism.
Zunsemetinib
go.drugbank.com/drugs/DB16502InvestigationalZunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis. … ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively.
Categories: Experimental Unapproved Treatments for COVID-19Metyrosine
go.drugbank.com/drugs/DB00765ApprovedInvestigationalIt is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) … An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines.
Phenserine
go.drugbank.com/drugs/DB04892InvestigationalPhenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia. … If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD.
Taberminogene vadenovec
go.drugbank.com/drugs/DB05011ExperimentalEG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC). … The initial target market is haemodialysis graft access surgery, a procedure in which patients whose kidneys have failed have a plastic tube grafted between blood vessels generally in their forearm so
Silmitasertib
go.drugbank.com/drugs/DB15408InvestigationalSilmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).
Categories: Casein Kinase II, antagonists & inhibitorsPegvisomant
go.drugbank.com/drugs/DB00082ApprovedInvestigationalPegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. … Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main